Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

ClinicalTrials.gov ID: NCT02584959

Public ClinicalTrials.gov record NCT02584959. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 3:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-blind, Placebo-controlled, Two-period, Three-sequence, Partial Crossover Study to Evaluate the Efficacy and Safety of Subcutaneous Administration of 2000 IU of C1 Esterase Inhibitor [Human] Liquid for Injection for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

Study identification

NCT ID
NCT02584959
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Shire
Industry
Enrollment
75 participants

Conditions and interventions

Interventions

  • C1 esterase inhibitor [human] liquid Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2015
Primary completion
Jul 23, 2017
Completion
Jul 23, 2017
Last update posted
Jun 7, 2021

2015 – 2017

United States locations

U.S. sites
16
U.S. states
12
U.S. cities
16
Facility City State ZIP Site status
Medical Research of Arizona Scottsdale Arizona 85251
AIRE Medical of Los Angeles Santa Monica California 90404
Bay Area Allergy Walnut Creek California 94598
IMMUNOe Research Centers Centennial Colorado 80112
Asthma and Allergy Associates PC Colorado Springs Colorado 80907
Atlanta Allergy and Asthma Clinic Marietta Georgia 30060
Institute For Asthma and Allergy Chevy Chase Maryland 20815
Washington University St Louis Missouri 63141
Allergy Asthma and Immunology Fair Lawn New Jersey 07410
Allergy Treatment Center of New Jersey Iselin New Jersey 08830
Clinical Research of Charlotte Charlotte North Carolina 28277
Bernstein Clinical Research Center Inc Cincinnati Ohio 45231
Clinical Research Solutions Middleburg Heights Ohio 44130
Allergy Clinic of Tulsa Tulsa Oklahoma 74133
AARA Research Center Dallas Texas 75231
Premier Clinical Research Spokane Washington 99202

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02584959, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 7, 2021 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02584959 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →